Condition: Prostate Cancer · BRCA Mutation · Mismatch Repair Gene Mutation · Sponsor: Institute of Cancer Research, United Kingdom
The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI/CT of the abdomen \& pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM.
This description comes directly from the study's public registry record.
Rosalind A Eeles, FRCP FRCR · +44 208 722 4483 · rosalind.eeles@icr.ac.uk
Elizabeth K Bancroft, PhD · +44 208 722 4483 · elizabeth.bancroft@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| Cancer Genetics Unit, Royal Marsden Hospital | London, Sutton, Surrey, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05097274